# Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

> **NCT02195973** · PHASE1 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** LDE225

## Key facts

- **NCT ID:** NCT02195973
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-12-10
- **Final completion:** 2017-09-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195973, "Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT02195973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*